```html

Kernicterus (Neurological Signs)

What is Kernicterus (neurological signs)?

Kernicterus is a rare but serious form of brain damage that occurs when high levels of unconjugated bilirubin cross the blood‑brain barrier and deposit in the basal ganglia, subthalamic nuclei, hippocampus, and cerebellum. The condition is most commonly seen in newborns with severe hyperbilirubinemia, but the term “kernicterus (neurological signs)” is also used to describe the constellation of neurologic findings that appear when bilirubin toxicity has already affected the central nervous system.

Neurologic signs may include abnormal muscle tone, movement disorders, hearing loss, oculomotor abnormalities, and cognitive impairment. If untreated, kernicterus can lead to permanent disability or death. Early recognition and treatment of elevated bilirubin are essential to prevent progression to kernicterus.

Common Causes

Several perinatal and maternal conditions can lead to dangerously high levels of unconjugated bilirubin. The most frequent contributors are:

• Hemolytic disease of the newborn (HDN) – maternal‑blood‑group incompatibility (e.g., Rh or ABO) causing rapid red‑cell destruction.
• Breast‑feeding jaundice – inadequate intake in the first days of life leading to dehydration and reduced bilirubin excretion.
• Breast‑feeding jaundice due to suboptimal latch – less milk intake → elevated bilirubin.
• Genetic enzyme deficiencies – e.g., G6PD deficiency, pyruvate kinase deficiency, or hereditary spherocytosis that increase red‑cell breakdown.
• Crigler‑Najjar syndrome type I – absent UDP‑glucuronosyltransferase activity, causing massive unconjugated hyperbilirubinemia.
• Physiologic newborn jaundice – immature liver conjugation that peaks between days 2‑5; risk rises with prematurity.
• Sepsis or pneumonia – increased bilirubin production and reduced hepatic clearance.
• Hypothyroidism – slows hepatic metabolism of bilirubin.
• Medication‑induced hemolysis – such as exposure to sulfonamides, certain antibiotics, or herbal remedies.
• Blood transfusion incompatibility – delayed hemolytic transfusion reactions can cause a bilirubin surge.

Associated Symptoms

Before neurologic damage becomes apparent, infants usually show signs of escalating jaundice. When kernicterus begins to affect the brain, the following symptoms may develop:

• Neurologic:
  • Hypotonia (floppy tone) progressing to hypertonia or spasticity
  • Choreoathetoid movements (involuntary writhing)
  • Arching of the back (opisthotonus)
  • Seizures, often focal or generalized
• Ophthalmic:
  • Paralysis of upward gaze (vertical gaze palsy)
  • Nystagmus, poor tracking
• Audiologic:
  • Sensorineural hearing loss, which may be unilateral or bilateral
• Developmental:
  • Delayed milestones (rolling, sitting, speech)
  • Cognitive impairment or learning difficulties later in childhood
• Other systemic clues:
  • Lethargy, poor feeding, temperature instability
  • High‑pitched cry or extreme irritability

When to See a Doctor

Newborn jaundice is common, but certain red‑flag features require prompt medical evaluation:

• Skin or sclera becoming yellow before 24 hours of age.
• Rapid progression of jaundice (e.g., moving from head to chest to abdomen within a few hours).
• Yellowing that spreads to the palms, soles, or mucous membranes.
• Any of the neurologic signs listed above (e.g., abnormal movements, seizures, poor eye movement).
• Feeding difficulty, lethargy, vomiting, or a high‑pitched cry.
• Infants born before 38 weeks gestation, < 2500 g, or with known hemolytic disorders.

When any of these occur, seek care immediately—ideally at a pediatric emergency department or a hospital with a neonatal intensive care unit (NICU).

Diagnosis

Diagnosing kernicterus involves confirming high levels of unconjugated bilirubin and identifying neurologic injury.

Laboratory Tests

• Serum total and direct bilirubin – a level > 20 mg/dL (≈340 µmol/L) in term infants or > 15 mg/dL in preterm infants is concerning.
• Complete blood count (CBC) and reticulocyte count – to assess hemolysis.
• Blood type and Coombs test – determines immune‑mediated hemolysis.
• G6PD screening – especially in populations with high prevalence.
• Liver function panel – rule out hepatic dysfunction that may impair conjugation.
• Thyroid function tests – hypothyroidism can exacerbate jaundice.

Imaging & Neuroassessment

• Transcranial ultrasound – early detection of basal‑ganglia echogenicity.
• MRI of the brain – shows characteristic T1‑weighted high signal in the globus pallidus and subthalamic nuclei.
• Auditory brainstem response (ABR) testing – evaluates sensorineural hearing loss.
• Neurodevelopmental assessment – usually performed by a pediatric neurologist or developmental specialist.

Clinical Scoring Systems

Tools such as the Bhutani nomogram (a bilirubin‑hour chart) help clinicians decide when phototherapy or exchange transfusion is needed to prevent kernicterus.

Treatment Options

Management focuses on rapidly lowering serum bilirubin and supporting the infant’s neurologic function.

Acute Medical Interventions

• Phototherapy – the first‑line treatment. Blue‑light (460‑490 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation. Intensive double‑surface phototherapy can reduce bilirubin by ≈ 0.5 mg/dL per hour.
• Exchange transfusion – indicated when bilirubin exceeds safe thresholds despite maximal phototherapy, or when neurologic signs appear. Whole blood is exchanged with compatible, screened donor blood to rapidly remove bilirubin‑laden erythrocytes.
• Intravenous immunoglobulin (IVIG) – useful in immune‑mediated hemolysis (e.g., ABO or Rh incompatibility) to reduce hemolysis and bilirubin rise.
• Hydration & feeding support – adequate caloric intake promotes stool bilirubin excretion. In severe cases, temporary tube feeding may be required.
• Phenobarbital (rarely) – can induce hepatic enzymes, but its use is limited to chronic conditions like Crigler‑Najjar type II.

Long‑Term / Supportive Care

• Physical & occupational therapy – to address motor deficits, spasticity, or movement disorders.
• Speech and language therapy – for hearing loss or speech delays.
• Audiologic rehabilitation – hearing aids or cochlear implants as indicated.
• Developmental monitoring – regular neuropsychological assessments throughout childhood.
• Family counseling – education about prognosis, genetic counseling for recurrent risk.

Prevention Tips

Because kernicterus is largely preventable, proactive measures are essential, especially in the first two weeks of life.

• Early newborn screening – universal bilirubin measurement before discharge (usually at 24 hours) and scheduled follow‑up checks.
• Promote effective breastfeeding – ensure proper latch, encourage feeding every 2–3 hours, and consider supplemental feeds if output is low.
• Identify at‑risk infants – preterm, low‑birth‑weight, multiple‑birth, or infants with known hemolytic disorders should have closer bilirubin monitoring.
• Maternal blood‑type and antibody testing – enables anticipatory management of Rh or ABO incompatibility.
• Vaccination and infection control – reduce neonatal sepsis, a trigger for rapid bilirubin rise.
• Avoid drugs that displace bilirubin – such as sulfonamides or certain NSAIDs in the first weeks of life.
• Educate caregivers – teach parents to recognize jaundice, monitor diaper output, and seek care if the infant appears unusually sleepy or difficult to awaken.
• Consider prophylactic phototherapy – in high‑risk scenarios (e.g., severe hemolysis) some centers initiate phototherapy before bilirubin reaches dangerous levels.

Emergency Warning Signs

Key Take‑aways

Kernicterus is a preventable neurological emergency caused by severe unconjugated hyperbilirubinemia. Early identification of risk factors, timely bilirubin measurements, and rapid initiation of phototherapy or exchange transfusion are the cornerstones of prevention. Once neurologic signs appear, multidisciplinary care—including neurology, audiology, and developmental specialists—is required to optimize outcomes.

References

• Mayo Clinic. Jaundice in newborns. https://www.mayoclinic.org/diseases-conditions/newborn-jaundice/diagnosis-treatment/drc-20374245 (accessed May 2026).
• American Academy of Pediatrics. Guidelines for the Management of Hyperbilirubinemia in the Newborn, 2022. https://www.aap.org/en-us/clinical-information/newborn-care/Pages/Hyperbilirubinemia.aspx.
• Centers for Disease Control and Prevention. Neonatal Jaundice. https://www.cdc.gov/ncbddd/jaundice/index.html.
• National Institutes of Health. Crigler‑Najjar Syndrome. https://www.ncbi.nlm.nih.gov/books/NBK1439/.
• Cleveland Clinic. Kernicterus: Symptoms, Causes, Treatment. https://my.clevelandclinic.org/health/diseases/21040-kernicterus.
• World Health Organization. Management of Neonatal Jaundice. https://apps.who.int/iris/bitstream/handle/10665/330023/9789241550180-eng.pdf.

```